anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Secondary insults, such as hypoxia and hypotension, may worsen a brain injury. We hypothesize that secondary brain insults may occur frequently during in-hospital transport in patients with traumatic brain injury (TBI). We additionally hypothesize that automated data collection devices used during transport could more reliably document the frequency of these events and help us to understand the causes. During transport of patients with TBI, intracranial pressure and arterial blood pressure will be continuously recorded to a monitor and saved for later analysis. Additional continuous measurements of pulse oximetry, end-tidal carbon dioxide, and mechanical ventilation settings will be made. The study will identify patients at risk for secondary insults, the etiology of these insults, and assist in development of a road map to prevent future incidents.
Zanaflex Capsules® or Zanaflex® tablets may be prescribed with or without food. Once the formulation has been selected and the decision to take with or without food has been made, this regimen should not be altered.

Food has complex effects on tizanidine pharmacokinetics, which differ with the different formulations. Zanaflex Capsules and Zanaflex tablets are bioequivalent to each other under fasting conditions (more than 3 hours after a meal), but not under fed conditions (within 30 minutes of a meal). These pharmacokinetic differences may result in clinically significant differences when switching administration of tablet and capsules and when switching administration between the fed or fasted state. These changes may result in increased adverse events, or delayed or more rapid onset of activity, depending upon the nature of the switch. For this reason, the prescriber should be thoroughly familiar with the changes in kinetics associated with these different conditions [see Clinical Pharmacology (12.3)].

The recommended starting dose is 2 mg. Because the effect of Zanaflex peaks at approximately 1 to 2 hours post-dose and dissipates between 3 to 6 hours post-dose, treatment can be repeated at 6 to 8 hour intervals, as needed, to a maximum of three doses in 24 hours. 

Dosage can be gradually increased by 2 mg to 4 mg at each dose, with 1 to 4 days between dosage increases, until a satisfactory reduction of muscle tone is achieved. The total daily dose should not exceed 36 mg. Single doses greater than 16 mg have not been studied.
This study aims to investigate the induction effect of LncRNA-CIR6 on MSC differentiation into cardiogenic cells in vitro and in vivo. In addition to pretreatment with Ro-3306 (a CDK1 inhibitor), LncRNA-CIR6 was transfected into BMSCs and hUCMSCs using jetPRIME. LncRNA-CIR6 was further transfected into the hearts of C57BL/6 mice via 100 μL of AAV9-cTnT-LncRNA-CIR6-ZsGreen intravenous injection. After three weeks of transfection followed by AMI surgery, hUCMSCs (5 × 105/100 μL) were injected intravenously one week later. Cardiac function was evaluated using VEVO 2100 and electric mapping nine days after cell injection. Immunofluorescence, Evans blue-TTC, Masson staining, FACS, and Western blotting were employed to determine relevant indicators. LncRNA-CIR6 induced a significant percentage of differentiation in BMSCs (83.00 ± 0.58)% and hUCMSCs (95.43 ± 2.13)% into cardiogenic cells, as determined by the expression of cTnT using immunofluorescence and FACS. High cTNT expression was observed in MSCs after transfection with LncRNA-CIR6 by Western blotting. Compared with the MI group, cardiac contraction and conduction function in MI hearts treated with LncRNA-CIR6 or combined with MSCs injection groups were significantly increased, and the areas of MI and fibrosis were significantly lower. The transcriptional expression region of LncRNA-CIR6 was on Chr17 from 80209290 to 80209536. The functional region of LncRNA-CIR6 was located at nucleotides 0-50/190-255 in the sequence. CDK1, a protein found to be related to the proliferation and differentiation of cardiomyocytes, was located in the functional region of the LncRNA-CIR6 secondary structure (from 0 to 17). Ro-3306 impeded the differentiation of MSCs into cardiogenic cells, while MSCs transfected with LncRNA-CIR6 showed a high expression of CDK1. LncRNA-CIR6 mediates the repair of infarcted hearts by inducing MSC differentiation into cardiogenic cells through CDK1.
The invention relates to a remote intelligent monitoring system for accurately monitoring the patient access amount, which comprises the following steps: step one: the Excel form preparation suitable for burn plastic department work is completed through the discussion of medical core members of the department and multiple modifications: the current input formula is a third army medical large burn fluid replacement formula, the later period can be adjusted according to the actual condition of the patient, and the rest of the input and output statistics are substituted into the table in a classified and respectively summed mode, so that the working efficiency of nursing staff is improved: 1. the program automatically calculates, reduces the time of manual statistics and error correction, and nurses can use more energy for the treatment and nursing aspects of patients. 2. The time point record is combined with the time period knot form, so that nurses can know and judge the illness state at the first time so as to report and process in time. 3. Program real-time statistics function, avoiding forgetting statistics phenomenon caused by busy emergency work. 4. Can be used for guiding nurses with low annual resources or insufficient experience of special departments.
Rationale: Noonan Syndrome Spectrum Disorders (NSSDs) are caused by pathogenic variants in genes of the Ras/MAPK signaling pathway, and belong to the RASopathy.

Lymphatic disease occur in 36% of patients with Noonan Syndrome (NS) during their lifetime, with different symptoms, severity, and onset. However, it is unknown how many patients with RASopathy are exactly impaired with lymph flow disorders, since many of these patients have unrecognized symptoms and go undiagnosed. For example, patients diagnosed with primary lymphedema (which implies being without known etiologic cause) may have an anatomic or functional abnormality of the central conducting lymph system that is not diagnosed as the causative lymph flow problem. With the diagnosis being based on the symptoms and not on the underlying pathophysiological mechanism, therapy will focus on diminishing symptoms and not on healing the pathophysiological cause. To eventually improve therapeutic intervention, a better understanding of the pathophysiology is necessary, and may be found by studying the central conducting lymphatic system of patients with NS and lymphatic disease, and adult volunteers with Noonan Syndrome without lymphatic disease. Objective: To get a better insight into the central conducting lymphatic system in adult volunteers with Noonan Syndrome (NS) without clinical symptoms or signs of lymphatic disease compared to NS and CardioFacioCutaan syndrome patients with severe lymphatic disease and healthy volunteers. (ongoing study: (Lymphomics; improving the understanding the anatomy of the lymphatic system and the direction and velocity of lymph flow; approved by the Medical Ethics Committee at Radboud University Medical Center Nijmegen file number 2021-7514) Study design: A single center, prospective collection of data Study population: Adult volunteers with Noonan Syndrome without (a history of) complaints or signs of lymphatic disease. Intervention: Three questionnaires (general health, lymphatic abnormalities and general MRI safety) will be taken prior to the dynamic MR lymphangiography. In addition to standard physical examination and electronic patient file screening, for inclusion and exclusion purposes. Subsequently, the MR lymphangiography will be performed. After 24 hours, the subject will be called for a follow-up by phone. Main study parameters/endpoints: the anatomy of the central lymph vessels, the velocity and direction of lymph flow, which can be compared with reference values. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participation in this study places subjects at minimal risk. Subjects will undergo placement of a small needle in an inguinal lymph node on both sides, with very little risk of bleeding and/or infection, as with other minimal invasive procedures. The dynamic MR lymphangiography will take approximately two hours
Unlike other diseases, respiratory diseases are not easy to treat even with modern medicine. For digestive diseases, an affected area may be cut out while looking through an endoscope, and medicine may be administered through the mouth to relieve a condition by directly contacting the affected area, or the administered medicine may travel through the blood and circulate throughout the body to improve the condition around the affected area. However, a respiratory organ is difficult to see through the endoscope, and orally administered medicine is delivered to the respiratory organ through the blood after passing through a digestive organ. A method of treating respiratory diseases of the present invention is not a method of oral administration or injection of medicine, but a method of sterilizing and removing germs or diseased cells by allowing medicine ingredients to directly enter the lungs which can be treated when breathing, wherein the method does not significantly affect other organs of the human body, such as the stomach or large intestine. There are plants that produce phytoncide which does not cause any problems to the human body even if ingredients enter the lungs and can sterilize and remove cancer cells and harmful bacteria. Cypress, Korean fir, cedar, pine, and sawara cedar which are representative plants release volatile substances with a biocidal effect through leaves to exterminate bacteria, fungi, and pests which interfere with survival. A scent of phytoncide comes from the leaves, and the phytoncide inside the leaves is extracted and placed in a container and released slowly. In addition, by squeezing out a juice and grinding the leaves in a blender, the phytoncide along with leaf ingredients is put in an open-top container (1) and placed under the nose. Accordingly, by inhaling the scent into the lungs, cancer cells, infectious bacteria, and harmful bacteria in the bronchi and lungs are sterilized and removed.
Attention deficit hyperactivity disorder (ADHD) is characterized by impulsiveness, hyperactivity, and inattention. It is seen primarily in children and adolescents and is often treated with psychostimulant medications. Osmotic-release oral system (OROS) methylphenidate, brand name Concerta, and mixed amphetamine salts extended release, brand name Adderall XR, are psychostimulant medications that have shown both efficacy (that they can have therapeutic benefits) and effectiveness (that they typically have therapeutic benefits in practice). Two newer psychostimulant medications-lisdexamfetamine dimesylate, brand name Vyvanse, and methylphenidate transdermal system, brand name Daytrana-have shown efficacy but have not been tested for effectiveness, nor have they been tested head-to-head against the older psychostimulants. This study will test the effectiveness, tolerability (lack of side effects), and acceptability (ease of use for patients) of the two newer psychostimulant medications and compare them to each other and to the two older psychostimulants.

Participation in this study will last 6 weeks, although some treatments may continue past the end of the study. At enrollment, participants will undergo a series of baseline evaluations. These will include interviews and assessments of ADHD symptoms, concurrent psychiatric disorders, medical and psychiatric history, family history of mental illness, risk and protective factors, other treatments, treatment expectancy of both the youth and parent, and vital signs. In consultation with their doctors, participants will be allowed to exclude zero, one, or two of the study medications; if they choose to exclude both of the new ADHD medications, they will not able to participate in the study. Participants will then be randomly assigned to one of the treatments they choose to include. They will receive a prescription for the medication and instructions for how to use it from their doctors; the study protocol does not specify a particular treatment regimen. Participants will undergo a second set of evaluations after 6 weeks of treatment or before, if the treatment ends earlier. This will include interviews and assessments similar to those administered at baseline as well as evaluation of any medication side effects.
There is a debate regarding the prediction of lymph node metastasis (LNM) in pedunculated T1 colorectal cancer (CRC). In this study with four cases of pedunculated T1 CRCs, we aimed to investigate gene expression variations based on the distance from the Haggitt line (HL) and identify potential molecular risk factors for LNM. By leveraging the Cancer Transcriptome Atlas and digital spatial profiling technology, we meticulously analyzed discrete regions, including the head, HL, proximal stalk region (300-1000 μm from HL), and distal stalk region (1500-2000 μm from HL) to identify spatially sequential molecular changes. Our findings showed significant overall gene expression variations among the head, proximal stalk, and distal stalk regions of pedunculated T1 CRCs compared to the control adenoma. Compared to LNM-negative T1 CRCs, LNM-positive T1 CRC showed that the expression of genes involved in immune-related pathways such as B2M, HLA-B, and HLA-E were significantly downregulated in the distal stalk region compared to the proximal stalk region. In summary, our results may tentatively suggest considering endoscopic resection of the stalk with a minimum 2000 μm margin from the HL, taking into account the gene expression alterations related to immune-related pathways. However, we acknowledge the limitations of this pilot study, notably the small case series, which may restrict the depth of interpretation. Further validation is imperative to substantiate these findings.
The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging π-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated. The complexes function when irradiated with low energy visible light with or without molecular oxygen.
Each child and his or her parent slept in a cleanroom for two weeks. Within 24 hours pre and post this two week experience blood and hair samples were taken from the children and the parents filled out rating scales.
<P>PROBLEM TO BE SOLVED: To provide an animal model for improving the immunogenicity of a human tumor and also forecasting the antitumor immune response of the human in order to provide an effective cancer immunotherapy.  <P>SOLUTION: The animal and method for evaluating vaccines are provided. Especially, a humanized animal model for evaluating the vaccines designed so as to confer immunity to pathogens of the human including the vaccines directed against human immunodeficiency virus (HIV) is provided. Further, it is associated with HIV vaccines, especially, attenuated replication competent HIV vaccines and replication defective HIV vaccines are provided. In addition, modified leishmania cells for expressing HIV proteins are provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
FIELD: medicine. SUBSTANCE: method involves recording electroencephalogram. Hypersynchronized electroencephalogram being found, narcotic treatment is administered with opioid analgesic preparations and α 2 -adrenoantagonist agents to reach stable monotonous strip on electroencephalogram and trunk activeness arrest. Then multiple mode stimulation is applied. The stable monotonous strip on electroencephalogram being found, multiple mode stimulation is carried out on the benzodiazipines application background. The benzodiazipines are administered at a dose not exceeding therapeutic efficiency of midasolam at a dose of 0.15 mg/kg. EFFECT: enhanced effectiveness of treatment. 5 cl, 8 dwg
On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive following intramuscular (IM) doses: Day 1 only: CAB long acting (LA) 800 mg (loading dose delivered as two 400 mg IM injections) + RPV LA 900 mg IM; Week 4 only: CAB LA 600 mg IM (second loading dose, no RPV); and from Week 8: CAB LA 600 mg IM +RPV LA 900 mg IM every 8 Weeks (Q8W) for 96 weeks. Eligible participants had the option to continue study participation in the Extension Period.
Alogliptin/Pioglitazone combination tablets, taken orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
This Phase II SBIR project represents the continuing development of an Information Technology Enabled Disease Management System for Treatment of Adolescent Depression (iTAD) following a highly successful Phase I award in which all Specific Aims were met. The need for this system innovation arises from the substantial costs that inadequately treated adolescent Major Depressive Disorder (MDD) has on the course of adolescent development and society as a whole. Effective treatments involving the combined use of a Selective Serotonin Reuptake Inhibitor (SSRI) and the administration of Cognitive Behavioral Therapy (CBT) is considered the "modal treatment" for adolescent MM. Yet, multiple barriers interfere with the implementation and dissemination of this "gold standard' of care. These barriers include: under recognition of depressive symptoms by parents and pediatricians, inability to assess adolescent depression accurately and reliably in primary care settings, safety concerns related to pharmacologic treatment, monitoring of symptom changes and adverse treatment effects, such as irritability and suicidal behavior, treatment non-compliance, lack of access to an integrated medical and treatment history; and an alarming shortage of properly trained child and adolescent psychiatrists capable of implementing optimal treatment safely, reliably, and effectively.

In this current project, the investigators are making tailored forms of CBT broadly and easily accessible to the community, using the iTAD (previously "ITEMS-TAD") which is intended to address these problems. Development of the system has continued and we have modified the existing prototype that was created with funding from federal sources (Phase 1). The technological infrastructure of the prototype includes a Computer Assisted Telephone Interview (CATI) platform, a database consisting of patients' real time medical and treatment history, and an underlying set of intelligent algorithms that tailors the intensity of the treatment resources and approaches administered in individual cases, with a special focus on identifying those enrolled adolescents needing more intensive or urgent care. When interacting with patients over the telephone, primary care nurses use the CATI to facilitate the reliable assessment of patient status and administer manualized, empirically informed interventions. The programming for the platform that delivers this intervention is complete and the debugging and refinement underway. The content for the remaining iTAD program has been developed and is being programmed. A Rapid Iterative Evaluation \& Testing (RITE) study was undertaken to refine the content of the application and assess the usability of the technology involved in its delivery; A field trial is underway to evaluate empirically indicators of efficacy and patient acceptance related to the ITEMS-TAD approach. The clinical trial of iTAD will begin in early April 2012. The investigators are currently enrolling depressed adolescents who will begin the trial shortly.
PCT No. PCT/FR95/00345 Sec. 371 Date Sep. 9, 1996 Sec. 102(e) Date Sep. 9, 1996 PCT Filed Mar. 21, 1995 PCT Pub. No. WO95/25542 PCT Pub. Date Sep. 28, 1995A composition containing a recombinant plasmid which includes an exogenous nucleotide sequence capable of expressing a compound including an amino acid sequence in a host organism. The composition includes an emulsion comprising at least one aqueous phase and at least one oily phase, the recombinant plasmid being contained in at least one of phases. A vaccine and a curative drug including the composition are also disclosed.
This invention relates to rifaximin for use in the treatment of bacterial vaginal infections. The invention also relates to the use for treating infections characterized by the presence of bacteria that may be clindamycin and/or metronidazole resistant. The invention also relates to the use of rifaximin to treat patients with vaginal infections who have relapsed following prior treatment or who have bacteria resistant to antibiotics other than rifaximin. This invention relates to rifaximin for use in the treatment of bacterial vaginal infections. The invention also relates to the use for treating infections characterized by the presence of bacteria that may be clindamycin and/or metronidazole resistant. The invention also relates to the use of rifaximin to treat patients with vaginal infections who have relapsed following prior treatment or who have bacteria resistant to antibiotics other than rifaximin. A method of producing vinyl polymer particles by suspension polymerization comprising: combining an aqueous media and a tricalcium phosphate to a reaction vessel; adding a p H stabilizing agent to the reaction vessel; adding a vinyl monomer to the reaction vessel; adding a peroxide initiator, e.g., which also generates CO2 as a result of primary or secondary decomposition, to the reaction vessel; adding surfactant or a water soluble free radical initiator to generate surfactant in situ to the reaction vessel; maintaining the reactor contents at greater than or equal to 90Â°C until a density of a dispersed phase becomes substantially equal to that of a continuous phase; adding a blowing agent to the reaction vessel; raising the temperature of the reaction vessel to greater than or equal to 100Â°C; and collecting polymer particles having a particle size distribution.